Published in J Neurosci on March 15, 1998
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation (2004) 2.91
CD36 mediates the innate host response to beta-amyloid. J Exp Med (2003) 2.65
Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation (2014) 1.83
Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A (1999) 1.74
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond) (2011) 1.73
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases. J Neuroimmune Pharmacol (2007) 1.28
Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ (2011) 1.25
The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation (2006) 1.25
Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia. J Biol Chem (2011) 1.17
Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol (2014) 1.14
Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) (2009) 1.13
Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol (2011) 1.13
Comprehensive analysis of tissue preservation and recording quality from chronic multielectrode implants. PLoS One (2011) 1.10
Microglia in Alzheimer's disease and transgenic models. How close the fit? Am J Pathol (1999) 1.09
The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease. J Signal Transduct (2012) 1.08
Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: an original strategy to avoid cell transplantation. PLoS One (2013) 1.07
Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in β-amyloid rat model of Alzheimer's disease. J Neuroinflammation (2012) 1.06
Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol (2012) 1.02
Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct (2006) 1.01
S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid Redox Signal (2011) 1.00
Amyloid fibrils trigger the release of neutrophil extracellular traps (NETs), causing fibril fragmentation by NET-associated elastase. J Biol Chem (2012) 0.98
The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease. Front Aging Neurosci (2014) 0.98
Differential cardiovascular responses to blockade of nNOS or iNOS in rostral ventrolateral medulla of the rat. Br J Pharmacol (2001) 0.96
Statins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically ill. Chest (2011) 0.96
Amyloid β-peptide directly induces spontaneous calcium transients, delayed intercellular calcium waves and gliosis in rat cortical astrocytes. ASN Neuro (2010) 0.95
Ocular changes in TgF344-AD rat model of Alzheimer's disease. Invest Ophthalmol Vis Sci (2014) 0.91
Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin. Oxid Med Cell Longev (2012) 0.91
Organic electrode coatings for next-generation neural interfaces. Front Neuroeng (2014) 0.90
Microglia and synapse: interactions in health and neurodegeneration. Neural Plast (2013) 0.89
CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging (2012) 0.85
Microglial responses to amyloid beta peptide opsonization and indomethacin treatment. J Neuroinflammation (2005) 0.85
Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease. J Alzheimers Dis (2007) 0.83
Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics (2007) 0.83
Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin Ophthalmol (2008) 0.82
The rat as an animal model of Alzheimer's disease. J Cell Mol Med (2009) 0.82
CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model. J Clin Invest (2014) 0.82
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis (2012) 0.80
Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci (2017) 0.79
CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci Rep (2016) 0.78
Alterations in Lipid Levels of Mitochondrial Membranes Induced by Amyloid-β: A Protective Role of Melatonin. Int J Alzheimers Dis (2012) 0.78
VIP enhances phagocytosis of fibrillar beta-amyloid by microglia and attenuates amyloid deposition in the brain of APP/PS1 mice. PLoS One (2012) 0.77
Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model. J Alzheimers Dis (2008) 0.77
Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum. PLoS One (2013) 0.76
Characterization of Novel Src Family Kinase Inhibitors to Attenuate Microgliosis. PLoS One (2015) 0.76
Stability of Aβ (1-42) peptide fibrils as consequence of environmental modifications. Eur Biophys J (2010) 0.76
Neuronal-glial Interactions Define the Role of Nitric Oxide in Neural Functional Processes. Curr Neuropharmacol (2012) 0.76
Correlated inflammatory responses and neurodegeneration in peptide-injected animal models of Alzheimer's disease. Biomed Res Int (2014) 0.76
Differential contributions of nitric oxide synthase isoforms at hippocampal formation to negative feedback regulation of penile erection in the rat. Br J Pharmacol (2002) 0.75
Deacetylation of TFEB promotes fibrillar Aβ degradation by upregulating lysosomal biogenesis in microglia. Protein Cell (2016) 0.75
Amyloid plaque structure and cell surface interactions of β-amyloid fibrils revealed by electron tomography. Sci Rep (2017) 0.75
Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux. Front Pharmacol (2015) 0.75
Nitric Oxide and Protein Disulfide Isomerase Explain the Complexities of Unfolded Protein Response Following Intra-hippocampal Aβ Injection. Cell Mol Neurobiol (2015) 0.75
Maternal depression and parenting behavior: a meta-analytic review. Clin Psychol Rev (2000) 8.05
Oxidation-reduction Potentials and Ferricyanide Reducing Activities in Peptone Cultures and Suspensions of Escherichia coli. J Bacteriol (1934) 6.10
Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science (1997) 4.03
Primary afferent tachykinins are required to experience moderate to intense pain. Nature (1998) 2.97
Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience (2002) 2.57
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med (2000) 2.54
Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science (1999) 2.43
Oxidation-reduction Potentials and Ferricyanide Reducing Activities in Glucose-peptone Cultures and Suspensions of Escherichia coli. J Bacteriol (1934) 2.37
Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry (2000) 2.37
Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience (2000) 2.28
The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J Struct Biol (2000) 2.26
The molecular dynamics of pain control. Nat Rev Neurosci (2001) 2.21
Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci (1999) 2.19
Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science (1995) 2.12
Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc Natl Acad Sci U S A (1988) 1.87
The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans (2005) 1.84
Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol (1993) 1.77
NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature (1997) 1.65
Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem (1996) 1.61
Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci U S A (1995) 1.60
Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry (1996) 1.58
Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry (1998) 1.54
Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J (1990) 1.51
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. Mayo Clin Proc (2001) 1.49
1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry (1995) 1.48
The differences in toxicity and release of bone-resorbing mediators induced by titanium and cobalt-chromium-alloy wear particles. J Bone Joint Surg Am (1993) 1.43
Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A (1992) 1.41
Urethral obstruction and bilateral ureteral hydronephroses secondary to fecal impaction. J Clin Gastroenterol (2000) 1.41
A beta deposition inhibitor screen using synthetic amyloid. Nat Biotechnol (1997) 1.37
Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci (1997) 1.33
Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J Neurosci (1999) 1.32
Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology (1996) 1.32
Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience (2010) 1.31
Novel peptide fragments originating from PGLa and the caerulein and xenopsin precursors from Xenopus laevis. J Biol Chem (1986) 1.30
Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci (2001) 1.28
Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. J Neurosci (1989) 1.27
Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry (1999) 1.27
Brain amyloid--a physicochemical perspective. Brain Pathol (1996) 1.27
Centrally administered orexin A increases motivation for sweet pellets in rats. Psychopharmacology (Berl) (2005) 1.23
Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience (1996) 1.22
Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. J Struct Biol (2000) 1.20
In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry (1996) 1.19
Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem (1993) 1.19
Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol (1995) 1.19
Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci U S A (1994) 1.19
Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res (2001) 1.19
Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo. J Neurosci (1997) 1.18
The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience (2011) 1.16
Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci U S A (1989) 1.15
Photoaffinity cross-linking of Alzheimer's disease amyloid fibrils reveals interstrand contact regions between assembled beta-amyloid peptide subunits. Biochemistry (2001) 1.14
Endothelin and the tumorigenic component of bone cancer pain. Neuroscience (2004) 1.14
Spinal opioid analgesia: how critical is the regulation of substance P signaling? J Neurosci (1999) 1.10
Correlation between inositol phospholipid hydrolysis and substance P receptors in rat CNS. Nature (1984) 1.09
Intestinal absorption and excretion of octapeptides composed of D amino acids. Proc Natl Acad Sci U S A (1994) 1.08
Naloxone blocks that portion of feeding driven by sweet taste in food-restricted rats. Am J Physiol (1995) 1.07
Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology (1995) 1.06